Safety Study of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension

NCT00686803 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

DRUG: PL3994
DRUG: Placebo

Sponsor

Palatin Technologies, Inc